![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Regeneron Resumes Enrollment for Lymphoma Drug Trials
Regeneron Resumes Enrollment for Lymphoma Drug Trials
![Regeneron logo](https://www.fdanews.com/ext/resources/test/Drug-Images4/Regeneron_Logo.png?t=1631745771&width=430)
Regeneron is restarting patient enrollment for two studies evaluating its investigational lymphoma drug, odronextamab, after the FDA lifted partial holds on the clinical trials.
The phase 1 and 2 studies assessing the therapy for follicular lymphoma and diffuse large B-cell lymphoma were paused in December after the FDA called for a change in the protocol following reports of cytokine release syndrome in some participants.
Odronextamab is a bispecific monoclonal antibody and antitumor agent that binds to T-cells and to malignant B-cells. Cytokine release syndrome, a sometimes fatal inflammatory response, is a known side effect of certain cancer therapies that bind to the CD3 proteins and co-receptors on T-cells.
Upcoming Events
-
21Oct